08:09 AM EDT, 07/17/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Wednesday it received a patent valid until 2040 from the US Patent and Trademark Office for UNI-494, its potential treatment for acute kidney injury or contrast-induced nephropathy.

Unicycive said UNI-494 is currently in an ongoing phase 1 clinical trial in the UK and recently received a US Food and Drug Administration Orphan Drug Designation for delayed graft function, a type of kidney injury.

Price: 0.4799, Change: +0.01, Percent Change: +1.67